Feasibility Study of Exenatide by Continuous Subcutaneous Infusion

NCT01857895 · Completed

Last updated 2026-05-28

This study tests how well a drug called exenatide, delivered by a small pump under the skin, is tolerated and used correctly in adults with obesity.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 10 people

Who can join Ages 18–60 · all sexes Healthy volunteers accepted.

Timeline Started 2013-05 · est. completion 2013-11

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT01857895 ↗

Description as written by the study sponsor.

This is an open-label study to investigate the feasibility of administering exenatide by continuous subcutaneous infusion to healthy subjects. Study will consist of two parts i.e. Part A and B. In Part A 2 healthy subjects will receive exenatide infusion over 24 hours followed by a follow-up visit 10 to 14 days after discharge from clinic. In Part B approximately 6 healthy subjects will receive subcutaneous infusions of exenatide for maximum of 7 days followed by a follow-up visit 10 to 14 days after discharge from clinic.

Treatments tested

Exenatide Drug

Prefilled pen containing 2.4 mL of drug will be transferred into MiniMed Paradigm Real-Time Revel device for subcutaneous infusion.

Main thing measured	Characterization of interruptions or deviations from prescribed exenatide infusion in Part A
Sponsor	GlaxoSmithKline
Conditions studied	Obesity
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01857895 ↗